Trulicity Dosage/Direction for Use

Posology: Adults: Monotherapy: The recommended dose is 0.75 mg once weekly.
Add-on therapy: The recommended dose is 1.5 mg once weekly.
For potentially vulnerable populations, such as patients ≥75 years, 0.75 mg once weekly can be considered as a starting dose.
Paediatric population (≥10 years old): The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly.
If additional glycemic control is needed, increase the dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage.
Combination therapy: When Trulicity is added to existing metformin and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued. When Trulicity is added to existing metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy, the current dose of metformin and/or SGLT2i can be continued. When it is added to existing therapy of a sulphonylurea or prandial insulin, a reduction in the dose of sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see Precautions and Adverse Reactions).
The use of Trulicity does not require blood glucose self-monitoring. Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea or prandial insulin, particularly when Trulicity therapy is started and insulin is reduced. A stepwise approach to insulin dose reduction is recommended.
Elderly patients (>65 years old): No dose adjustment is required based on age (see Pharmacology: Pharmacokinetics under Actions). However, the therapeutic experience in patients ≥75 years is very limited (see Pharmacology: Pharmacodynamics under Actions), and in these patients 0.75 mg once weekly can be considered as a starting dose.
Patients with renal impairment: No dosage adjustment is required in patients with mild, moderate or severe renal impairment (eGFR <90 to ≥15 mL/min/1.73 m²).
There is very limited experience in patients with end stage renal disease (<15 ml/min/1.73 m²), therefore, Trulicity cannot be recommended in this population (see Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions).
Patients with hepatic impairment: No dosage adjustment is required in patients with hepatic impairment.
Method of administration: Trulicity is to be injected subcutaneously in the abdomen, thigh or upper arm. It should not be administered intravenously or intramuscularly.
The dose can be administered at any time of day, with or without meals.
If a dose is missed, it should be administered as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose. If less than 3 days (72 hours) remain before the next scheduled dose, the missed dose should be skipped and the next dose should be administered on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
The day of weekly administration can be changed if necessary, as long as the last dose was administered 3 or more days (72 hours) before.